WG
ITOS

Winton Group’s iTeos Therapeutics ITOS Stock Holding History

Winton Group’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-33,433
Closed -$366K – 797
2023
Q3 		$366K Buy
33,433
+21,221
+174% +$271K 0.03% 470
2023
Q2 		$162K Sell
12,212
-6,218
-34% -$88.7K 0.01% 686
2023
Q1 		$251K Sell
18,430
-1,097
-6% -$19.7K 0.02% 861
2022
Q4 		$381K Sell
19,527
-29,376
-60% -$574K 0.03% 719
2022
Q3 		$932K Sell
48,903
-3,361
-6% -$77.4K 0.06% 439
2022
Q2 		$1.08M Buy
52,264
+40,883
+359% +$970K 0.06% 461
2022
Q1 		$366K Buy
+11,381
New +$414K 0.02% 767

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Winton Group's ITOS Position: Q4 2023 in Review

Winton Group sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 33,433 shares — an estimated $366K sold.

Winton Group first reported a position in ITOS in Q1 2022 and held it in 7 quarters. The position peaked at $1.08M in Q2 2022. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • Winton Group reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Winton Group sold 33,433 iTeos Therapeutics shares in Q4 2023, an estimated $366K.
  • Winton Group first reported a position in iTeos Therapeutics in Q1 2022 and held it in 7 quarters.
  • Winton Group's iTeos Therapeutics position peaked at $1.08M in Q2 2022.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Winton Group's 13F filing for Q4 2023, filed 12 Feb 2024.